These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 32915863)

  • 1. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
    Li G; Zhang L; DiBernardo A; Wang G; Sheehan JJ; Lee K; Reutfors J; Zhang Q
    PLoS One; 2020; 15(9):e0238843. PubMed ID: 32915863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.
    Pilon D; Joshi K; Sheehan JJ; Zichlin ML; Zuckerman P; Lefebvre P; Greenberg PE
    PLoS One; 2019; 14(10):e0223255. PubMed ID: 31600244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.
    Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
    J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?
    Pilon D; Sheehan JJ; Szukis H; Morrison L; Zhdanava M; Lefebvre P; Joshi K
    J Affect Disord; 2019 Aug; 255():50-59. PubMed ID: 31128505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a United States-based retrospective claims database analysis.
    Bangalore S; Shah R; Gao X; Pappadopulos E; Deshpande CG; Shelbaya A; Prieto R; Stephens J; Chambers R; Schepman P; McIntyre RS
    J Med Econ; 2020 Mar; 23(3):262-270. PubMed ID: 31665949
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System.
    Sussman M; O'sullivan AK; Shah A; Olfson M; Menzin J
    J Manag Care Spec Pharm; 2019 Jul; 25(7):823-835. PubMed ID: 31232205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental Health Care Burden of Treatment-Resistant Depression Among Commercial, Medicaid, and Medicare Payers.
    Shrestha A; Roach M; Joshi K; Sheehan JJ; Goutam P; Everson K; Heerlein K; Jena AB
    Psychiatr Serv; 2020 Jun; 71(6):593-601. PubMed ID: 32237982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression.
    Olfson M; Amos TB; Benson C; McRae J; Marcus SC
    J Manag Care Spec Pharm; 2018 Mar; 24(3):226-236. PubMed ID: 29485948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Evaluation of the Clinical and Economic Burden Among Older Adult Medicare-Covered Beneficiaries With Treatment-Resistant Depression.
    Benson C; Szukis H; Sheehan JJ; Alphs L; Yuce H
    Am J Geriatr Psychiatry; 2020 Mar; 28(3):350-362. PubMed ID: 31735488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder.
    Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
    Curr Med Res Opin; 2021 Jan; 37(1):123-133. PubMed ID: 33124940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic burden of treatment-resistant depression among veterans in the United States.
    Szukis H; Joshi K; Huang A; Amos TB; Wang L; Benson CJ
    Curr Med Res Opin; 2021 Aug; 37(8):1393-1401. PubMed ID: 33879005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database.
    Amos TB; Tandon N; Lefebvre P; Pilon D; Kamstra RL; Pivneva I; Greenberg PE
    J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29474009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database.
    Kubitz N; Mehra M; Potluri RC; Garg N; Cossrow N
    PLoS One; 2013; 8(10):e76882. PubMed ID: 24204694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom.
    Denee T; Ming T; Waller J; Bailey T; Rajkovic-Hooley O; Middleton-Dalby C; Le HH; Zhang Q; McCrone P; Taylor D
    Curr Med Res Opin; 2021 Feb; 37(2):311-319. PubMed ID: 33253055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Cognitive Function and Health Care Costs 3 Months and 6 Months After Initiating Antidepressant Medication for Depressive Disorders.
    Walker V; Patel H; Kurlander JL; Essoi B; Yang J; Mahableshwarkar AR; Samp JC; Akhras KS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):742-52, 752a-752e. PubMed ID: 26308222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis.
    Gauthier G; Guérin A; Zhdanava M; Jacobson W; Nomikos G; Merikle E; François C; Perez V
    BMC Psychiatry; 2017 Jun; 17(1):222. PubMed ID: 28629442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder.
    Schultz J; Joish V
    Psychiatr Serv; 2009 Dec; 60(12):1604-11. PubMed ID: 19952150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world treatment modalities, health care resource utilization, and costs among commercially insured patients with newly diagnosed major depressive disorder in the United States.
    Pizzicato LN; Xie RZ; Yang Y; Grabner M; Chapman RH
    J Manag Care Spec Pharm; 2023 Jun; 29(6):614-625. PubMed ID: 37276037
    [No Abstract]   [Full Text] [Related]  

  • 19. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study.
    Lundberg J; Cars T; Lööv SÅ; Söderling J; Sundström J; Tiihonen J; Leval A; Gannedahl A; Björkholm C; Själin M; Hellner C
    JAMA Psychiatry; 2023 Feb; 80(2):167-175. PubMed ID: 36515938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
    CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.